Project Grant R44CA291420
Award Date
8/5/24
Completion Date
7/31/26
Dollars Obligated
$898K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21231, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $1,003,173 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Radiopharmaceutical Imaging and Dosimetry, LLC to develop a prototype web/cloud-based quantitative SPECT reconstruction software system for clinical trials and dosimetry of radiopharmaceutical therapy (RPT) using alpha-emitting radionuclides. The key objectives are to: 1) improve existing quantitative SPECT methods by enhancing scatter and downscatter modeling and adding partial...
This federal Project Grant award of $644,622 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to enhance radioligand therapy for prostate cancer through the development of biomarker and dosimetry-guided personalized treatment approaches. The key objectives are to: 1) develop a novel method for bone marrow dosimetry using macro/micro Monte Carlo modeling, 2) build predictive models to estimate absorbed radiation doses from pre-therapy PET...
This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop an innovative radiation imaging tool to support the advancement of targeted alpha cancer therapies. The $811,503 award to Qscint Imaging Solutions LLC, located in Tucson, AZ, will fund the refinement of an algorithm for real-time isotopic spectroscopy...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $581,723 to The Johns Hopkins University to develop an advanced imaging system called the Alpha-Scope for in vivo 3D autoradiography of radiopharmaceuticals and their radioactive daughter products in small animal studies. The goal is to create a hyperspectral single-photon emission microscope system that can map the microscale distribution of alpha- and beta-emitting...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $644,034 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop a nanoparticle-based drug delivery platform that uses radiation therapy to trigger the localized release of chemotherapy within tumor tissue. The goal is to improve the therapeutic window of chemoradiation treatment by enhancing tumor control while mitigating systemic toxicities....
The National Cancer Institute (NCI) awarded a $596,095 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Washington. The grant will support the development and validation of the Personalized Remote Radiation Tracking Portable Organ Dosimetry Device (PRRT PODD), a patient-friendly technology that enables personalization of 177Lu-DOTATATE therapy for neuroendocrine tumor patients. The project aims to design compact imaging detectors and software tools for...
The National Cancer Institute (NCI) awarded a $696,447 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Rector & Visitors of the University of Virginia to develop and evaluate a 203Pb/212Pb isotope-based SPECT imaging and targeted alpha therapy as precision therapeutic tools for mesothelioma. The project aims to target a tumor-selective CD46 epitope expressed across all major mesothelioma subtypes using a novel human monoclonal antibody. The research will assess...
The National Cancer Institute (NCI) awarded a $185,760 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Regents of the University of California, San Francisco (UCSF) to develop a novel tumor-targeted combination therapy for metastatic castration-resistant prostate cancer (mCRPC). The project aims to enhance efficacy and reduce toxicity by co-delivering cytotoxic drugs and the radioactive isotope Actinium-225 directly to cancer cells. Key objectives include developing...
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $1,149,264 Project Grant under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to The University of Texas MD Anderson Cancer Center. The grant, awarded on March 1, 2025 with a final completion date of February 28, 2029, will support the development of a rapid, inexpensive microfluidics-based approach for dose-on-demand production of ready-to-inject...
This Project Grant award of $676,567.00 was provided by the National Cancer Institute (NCI), under the federal Cancer Treatment Research program (CFDA 93.395), to The Regents of the University of California, San Francisco (UCSF). The award will fund a multi-year research project to systematically test a transforming growth factor beta (TGFB) targeted theranostic radiopharmaceutical therapy approach across preclinical cancer models. The research aims to assess the biological effectiveness of...